July 29, 2020JAMA Cardiology174 citationsOpen Access
One-Year Outcomes of Mitral Valve-in-Valve Using the SAPIEN 3 Transcatheter Heart Valve
Structured PICO
Does transcatheter mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve improve outcomes in patients with failed surgical bioprosthetic valves?
P
Population
Patients with failed surgical bioprosthetic valves and favorable anatomy
I
Intervention
Transcatheter mitral valve-in-valve (MViV) using the SAPIEN 3 transcatheter heart valve (transseptal approach)
O
Outcome
Technical success, 30-day and 1-year mortality, heart failure symptoms, and valve performance
Transseptal mitral valve-in-valve using the SAPIEN 3 valve is a viable option with high success and low mortality at 1 year for patients with failed surgical bioprostheses.
Abstract
Transcatheter MViV using the SAPIEN 3 transcatheter heart valve is associated with high technical success, low 30-day and 1-year mortality, significant improvement of heart failure symptoms, and sustained valve performance. Transseptal MViV should be considered an option for most patients with failed surgical bioprosthetic valves and favorable anatomy.